Background: may have a protective effect against inflammatory bowel disease (IBD). We integrated epidemiological data to identify the correlation between IBD and . Moreover, we analyzed whether IBD medication and classification affect , and whether eradication of leads to recurrence of IBD.
Methods: Articles published up to May 1, 2019, in three main databases including PubMed, MEDLINE and Embase, were searched. Study types included cross-sectional studies, retrospective studies and perspective studies, and data were combined and analyzed. Spearman correlation analysis and meta-analysis were performed after collecting and collating the relevant data. Sensitivity analysis and meta-regression were used to evaluate reliability and heterogeneity.
Results: Fifty-nine studies on IBD prevalence, 127 studies on prevalence, and 23 studies for meta-analysis were included. IBD, ulcerative colitis (UC) and Crohn's disease (CD) were negatively correlated to prevalence (all <0.001). The meta-analysis results showed that compared to controls, the odds of having infection were 0.44, 0.36, 0.54 for IBD, CD and UC, respectively (OR=0.44, 95% CI=0.34-0.59; OR=0.36, 95% CI=0.26-0.49; OR=0.54, 95% CI=0.4-0.72). Moreover, IBD patients were 1.41 times (OR=1.41, 95% CI=1.25-1.58) more likely to relapse after eradication of . Finally, infection was not related to IBD medication and classification.
Conclusion: prevalence was negatively correlated to IBD and had a protective effect against IBD. Furthermore, eradication of can lead to recurrence of IBD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.34172/aim.2021.44 | DOI Listing |
J Clin Psychiatry
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
We compared substance use disorder (SUD) prevalence among adult inflammatory bowel disease (IBD) hospitalizations with non-IBD controls from the 2016-2018 National Inpatient Sample, assessing correlations with demographics, socioeconomic status, geographic regions, depression, and anxiety. The primary aim focused on SUD, defined as substance abuse or dependence (: F10-F19) excluding unspecified use or remission, among hospitalizations documenting IBD (Crohn's disease or ulcerative colitis; : K50-51) as one admitting diagnosis (IBD-D). The prevalence of SUD among hospitalizations with and without IBD was compared.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
GI Biopharma Inc, Westfield, NJ, USA.
J Crohns Colitis
January 2025
Medical School of Nanjing University, Department of General Surgery, Jinling Hospital, Nanjing 210002, China.
Background: Impaired intestinal epithelial barrier has been considered to be associated with an increasing variety of gastrointestinal diseases, especially inflammatory bowel disease (IBD) encompassing Crohn's disease (CD) and ulcerative colitis (UC). We aimed to investigate the role of Gasdermin B (GSDMB) in modulating intestinal epithelial barrier integrity and proposed a promising therapeutic strategy.
Methods: GSDMB expression was evaluated in adult CD samples by molecular biology means and single-cell transcriptomes.
J Pediatr Gastroenterol Nutr
January 2025
Department of Pediatrics, Division of Pediatric Gastroenterology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Objectives: Fecal calprotectin (FC) is a marker commonly used in the diagnosis and follow-up of inflammatory bowel diseases (IBD). However, other gastrointestinal conditions, like H. pylori (HP) infection, can result in increased neutrophil activity as well.
View Article and Find Full Text PDFPathol Oncol Res
January 2025
Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Objective: Recently, several non-conventional variants of IBD-associated dysplasia have been described; however, their prevalence in Central-Eastern Europe is unknown. We aimed to perform a retrospective pilot study by re-evaluating several IBD-associated adenocarcinoma cases to survey the incidence of adjacent non-conventional dysplasia and validate that recent North American findings may apply to a European population.
Methods: Retrospectively, 28 randomly chosen cases of IBD-associated adenocarcinomas diagnosed between 2010 and 2022 were re-evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!